User Posts: admin3
0
Lifileucel Is Efficacious in Advanced Mucosal Melanoma
0

Clinical trial data showed that lifileucel was efficacious in treating mucosal melanoma that progressed on immunotherapy. Lifileucel led to improvements in ...

0
Trodelvy Offers Antitumor Activity in Pretreated Head and Neck Cancer
0

Treatment of Trodelvy (sacituzumab govitecan-hziy) led to durable antitumor activity with predominant gastrointestinal toxicities in patients with ...

0
The path to prevention is paved with biological insight – Cancer Research UK
0

Dr Elise Rees is postdoctoral scientist in Professor Kwee Yong’s Multiple Myeloma Laboratory at the UCL Cancer Institute, and co-investigator on a ...

0
How Socks Help Patients with Cancer
0

One dreary day after finishing a long day of Taxol chemo in 2018, I came home to a package addressed to me from HallieStrong. I did not recognize them name ...

0
Patient Anatomy Can Help Predict Prostate Cancer Side Effects
0

Dr. Kiran Nandalur (left), a radiologist with Corewell Health and principal investigator of a new study that could help predict radiation side effects for ...

0
Cancer Data from European Conference May Lead to FDA Approvals
0

Last week, the European Society of Medical Oncology (EMSO) held their annual Congress in Madrid. The conference brought together cancer researchers from ...

0
FDA Approves Loqtorz Regimens for Advanced Nasopharyngeal Carcinoma
0

tThe FDA approved two Loqorz-based regimens for patients with nasopharyngeal carcinoma. The Food and Drug Administration (FDA) approved Loqtorz ...

0
For Patients with MPNs, Managing Early Satiety ‘Can Be Really Tricky’
0

Patients with myeloproliferative neoplasms (MPNs) — blood cancers that cause the bone marrow to overproducer red or white blood cells or platelets, ...

0
Jemperli Plus Chemo Continues to Demonstrate Strong Outcomes in Advanced NSCLC
0

Jemperli plus chemotherapy improved objective response rate and overall survival in patients with nonsquamous non-small cell lung cancer. Patients with ...

0
Tecentriq and Zejula Plus Chemo Did Not Offer Better Outcomes in Recurrent Ovarian Cancer
0

Patients with recurrent ovarian cancer (ROC) did not experience better outcomes when receiving maintenance therapy with immunotherapy Tecentriq ...

User Deals: admin3
Browsing All Comments By: admin3
CML Alliance
Logo
Enable registration in settings - general
Compare items
  • Total (0)
Compare
0
Shopping cart